Advanced Search
Current and Breaking News for Professionals, Consumers and Media



Click here to learn how to advertise on this site and for ad rates.

Heart Health Author: Staff Editor Last Updated: Sep 26, 2017 - 10:29:38 AM



Gene Therapy Improved Left Ventricular and Atrial Function in Congestive Heart Failure by up to 25 Percent

By Staff Editor
Sep 26, 2017 - 10:26:13 AM



Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon Sign up for our Ezine
For Email Marketing you can trust


Email this article
 Printer friendly page

(HealthNewsDigest.com) - Heart function improved by up to 25 percent in a trial using gene therapy to reverse cardiac damage from congestive heart failure in a large animal model, Mount Sinai researchers report. This is the first study using a novel vector for gene therapy to improve heart function in non-ischemic heart failure.

The results of the study will be published online in the Journal of the American College of Cardiology on Monday, September 25, at 2 pm.

In heart failure, a weakened or damaged heart no longer pumps blood effectively. This potentially fatal disease affects almost 6 million Americans, according to the American Heart Association, and is a major cause of morbidity and mortality, especially in elderly patients. Despite this toll, there has been little progress toward any kind of cure. Novel therapeutic approaches, such as gene therapy and cell therapy, hold the promise of complementing or replacing existing therapies for congestive heart failure.

“Mount Sinai has performed pioneering work on gene therapy over the last decade, and this study shows that gene therapy is now a viable option for treating congestive heart failure,” said the study’s senior author, Roger Hajjar, MD, Director of the Cardiovascular Research Center and the Arthur and Janet C. Ross Professor of Medicine at the Icahn School of Medicine at Mount Sinai. “There is a critical need to explore new therapeutic avenues and approaches.”

This study featured two independent experiments. The first established the safety of administering a therapeutic gene delivery vector, BNP116, created from an inactivated virus over three months, into 48 pigs without heart failure through the coronary arteries via catheterization using echocardiography. The second experiment examined the efficacy of the treatment in 13 pigs with severe heart failure induced by mitral regurgitation. Six pigs received the gene and 7 received a saline solution.

The researchers determined that the gene therapy was safe and significantly reversed heart failure by 25 percent in the left ventricle and by 20 percent in the left atrium. Heart failure often results in enlarged hearts, and the team found a 10 percent reduction of heart size in the affected animals. Heart failure in the cohort of pigs treated with saline worsened.

The research team plans to study the same gene therapy in a human trial starting next year. The gene vector has been approved by the Food and Drug Administration for clinical treatment.

This study was supported by NIH P50 HL112324, R01 HL119046, R01 HL117505, R01HL128099, R01 HL129814, R01HL131404, & R43HL108581 (R. J. H.), HL26057, & HL64018 (E.G. K) and a Transatlantic Leducq Foundation grant.  The Gene Therapy Resource Program (GTRP) of the National Heart, Lung, and Blood Institute, National Institutes of Health provided some of the gene vectors used in this study. K.I is supported by a grant from American Heart Association 17SDG33410873.

###



Top of Page

HealthNewsDigest.com

Heart Health
Latest Headlines


+ Coordinated Emergency Care Improves Survival for Patients with Heart Attacks
+ Clot-Busting Drugs Not Recommended for Most Patients with Blood Clots
+ Screening for Critical Congenital Heart Disease at Birth Saves Lives
+ Blood Pressure Begins to Decline 14 Years Before Death
+ Stress Causes Stress on Hearts
+ Meeting Higher Standards for Lowering Blood Pressure
+ Some Cancer Therapies May Provide a New Way to Treat High Blood Pressure
+ Could This Protein Protect People Against Coronary Artery Disease?
+ New Tool Predicts Risk of Heart Attack in Older Surgery Patients
+ When Heartburn Lingers Too Long



Contact Us | Job Listings | Help | Site Map | About Us
Advertising Information | HND Press Release | Submit Information | Disclaimer

Site hosted by Sanchez Productions